Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor- and interleukin-6 in patients with polycystic ovary syndrome |
Kim, Chung-Hoon
(Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine)
Ahn, Jun-Woo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) You, Rae-Mi (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Sung-Hoon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Chae, Hee-Dong (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Kang, Byung-Moon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) |
1 | Garruti G, Depalo R, Vita MG, Lorusso F, Giampetruzzi F, Damato AB, et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online 2009;19:552-63. DOI ScienceOn |
2 | Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005;25:244-52. DOI ScienceOn |
3 | ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 2009;114:936-49. DOI ScienceOn |
4 | Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril 2010;94:236-41. DOI ScienceOn |
5 | Vural P, Degirmencioglu S, Saral NY, Akgul C. Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2010;150:61-5. DOI ScienceOn |
6 | Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009;26:163-70. DOI |
7 | Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003;101:1177-82. DOI ScienceOn |
8 | Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 2002;17:426-31. DOI ScienceOn |
9 | Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25. |
10 | Richter ON, Dorn C, Rosing B, Flaskamp C, Ulrich U. Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis. Arch Gynecol Obstet 2005;271:143-7. DOI ScienceOn |
11 | Demir B, Guven S, Guven ES, Atamer Y, Gul T. Serum IL-6 level may have role in the pathophysiology of unexplained infertility. Am J Reprod Immunol 2009;62:261-7. DOI ScienceOn |
12 | Elkind-Hirsch KE. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: impact on metabolic and reproductive abnormalities. Treat Endocrinol 2006;5:171-87. DOI ScienceOn |
13 | Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue: understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007;92:386-95. DOI |
14 | Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-5. DOI ScienceOn |
15 | Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-39. DOI ScienceOn |
16 | Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010;22:466-76. DOI ScienceOn |
17 | Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update 2011;17:17-33. DOI ScienceOn |
18 | Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 2008;153:636-45. DOI ScienceOn |
19 | Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, et al. Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol 2009;7:147. DOI |
20 | Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function: implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol 2005;3:41. DOI |